Argentum Pharmaceuticals and Eli Lilly Settle Patent Dispute Over CIALIS®
August 22 2017 - 8:00PM
PR Newswire (US)
NEW YORK, Aug. 22, 2017 /PRNewswire/ -- Argentum
Pharmaceuticals LLC, a generic pharmaceutical company, announced
that it has reached a settlement and license agreement with Eli
Lilly and Company related to Argentum's generic version of CIALIS®
(tadalifil).
The agreement generally provides that Argentum may commence
marketing its generic product no earlier than September 27, 2018. The specific date on which
Argentum may launch its generic product and other details
concerning the settlement have not been disclosed.
CIALIS® is a registered trademark of Eli Lilly and Company.
View original content with
multimedia:http://www.prnewswire.com/news-releases/argentum-pharmaceuticals-and-eli-lilly-settle-patent-dispute-over-cialis-300508183.html
SOURCE Argentum Pharmaceuticals LLC
Copyright 2017 PR Newswire